Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Safety and efficacy of zanubrutinib in waldenstrom macroglobulinemia patients treated in common clinical practice: A retrospective-prospective study by fondazione italiana linfomi (FIL)

View Full Paper
Ask AI
Bookmark
Share

Authors

FAFrancesco AutoreUniversità Cattolica del Sacro CuoreFPFrancesco PiazzaUniversity of PaduaGDGiulia DaghiaAzienda Unità Sanitaria Locale di Ferrara

Discussion

Loading...

Member takes

Overview

Retrospective-prospective study reveals safety and effectiveness of zanubrutinib in Waldenström patients, indicating favorable outcomes amidst common adverse events.

Key Points

  • Evaluate the safety and efficacy of zanubrutinib in Waldenström macroglobulinemia patients in clinical practice.
  • Retrospective-prospective multicenter study involving 99 patients
  • Patients treated with zanubrutinib outside clinical trial from October 2020 to July 2025
  • Assessments included treatment management, adverse events and overall response rates
  • 89% of patients remained on treatment after a median of 12 months
  • Overall response rate of 89.7%, with 100% in treatment-naïve patients
  • Median progression free survival at 12 months was 92%

Cite This Study

Autore et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db2ahttps://doi.org/10.1182/blood-2025-5360
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of zanubrutinib in patients with non-IgM lymphoplasmacytic lymphoma2025
  2. 2Efficacy and safety of zanubrutinib in Waldenström macroglobulinemia: A systematic review and meta-analysis of clinical trials.2026
  3. 3Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL).2024 · 2 citations
  4. 4Dose modifications, discontinuation patterns and PFS of zanubrutinib in 410 CLL/SLL patients – a nationwide real-world cohort2026
  5. 5Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.2025